New metric defines areas of highest prostate cancer burden

April 26, 2018

(PHILADELPHIA) - To catch prostate cancer at earlier stages, when it's more easily treated, many institutions do community outreach and education sessions to explain why cancer screenings can be life-saving. In order to have the highest impact, however, institutions must select where to focus their efforts. Prostate cancer is most common among African American men and can be more aggressive in African American and men in a low socioeconomic bracket. Therefore, many institutions base their outreach on these two demographic factors. However, work recently published in the journal Preventive Medicine shows that this may not be the best approach and offers another method for identifying areas with the highest prostate cancer burden.

"We know that not every man in a high risk demographic will develop prostate cancer," said senior author Charnita Zeigler-Johnson, PhD, MPH, researcher with the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, one of only 69 NCI-Designated Centers and only one of eight to have a prostate cancer program of excellence. "We've seen that often the same programs and organizations are targeted for education and outreach efforts. We realized that we're probably leaving out large areas of the city that potentially have higher risk. I wanted to create a more effective tool to find those areas."

To do that, Dr. Zeigler-Johnson's team including SKCC Consortium partners crunched data from the Pennsylvania Cancer Registry that covered a span of nine years (from 2005 to 2014) and looked specifically at prostate cancer cases in the city of Philadelphia. Using that data as a starting point the researchers then created a prostate cancer composite score that would help identify census tracts with the highest burden of prostate cancer. The score was based on three factors: 1) a standardized incidence ratio (SIR), which measures how much more likely a population is to get cancer compared to national rates 2) mortality ratio, which similarly determines the rate of death from prostate cancer compared to national rates and 3) how advanced the prostate cancer was at diagnosis.

"None of these factors alone can be used to categorize burden of the disease. We found they were more predictive when combined," said Dr. Zeigler-Johnson, who is also Assistant Professor of Medical Oncology at Jefferson (Philadelphia University + Thomas Jefferson University.

The researchers then used mapping software to geographically identify census tracts with the highest scores. "We were surprised to find clusters of high burden that did not always overlap with the areas with the largest concentrations of African Americans or those with lowest socioeconomic status measures," said first author Russell McIntire, PhD, MPH, an Assistant Professor in the Jefferson College of Population Health.

"We are seeing the highest prostate cancer burden cluster in tight geographic areas," said Dr. Zeigler-Johnson, whose earlier work suggested similar trends. "We think it's worth studying why these areas of the city are at higher risk for poor prostate cancer outcomes. Could it be that neighborhoods share similar practices and norms, or lack of awareness about prostate cancer risk? At this point it's too early to tell."

Although the tool was developed for prostate cancer, the method could be developed and applied to other cancer types in order to hone educational outreach efforts for the greater impact.

Now that Dr. Zeigler-Johnson and colleagues have identified areas of high prostate cancer risk in Philadelphia, they will develop, implement, and test an educational outreach program. "Testing our assumptions in the community will help us determine if this tool can be more effective than outreach targeted using traditional methods," said Dr. Zeigler-Johnson.
This research was supported by U.S. Department of Defense Grant #DODW81XWH-15-1-0693, and pilot funding from the Sidney Kimmel Cancer Center at Jefferson Health. The funders had no role in the study design, conduct of the experiments, and interpretation of the data.

Article reference: Russell K. McIntire, Scott W. Keith, Maxwell Boamah, Amy E. Leader, Karen Glanz, Ann C. Klassen, Charnita M. Zeigler-Johnson, "A Prostate Cancer Composite Score to Identify High Burden Neighborhoods," Preventive Medicine, DOI: 10.1016/j.ypmed.2018.04.003, 2018.

Media Contact: Edyta Zielinska,, 215-955-7359.

Thomas Jefferson University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to